The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

This not only leads to resistance of ovarian cancer cells to chemo-immunotherapy drugs, but also promotes invasion and metastasis of ovarian cancer cells. Therefore, elucidating the mechanism of ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...